Immunoclassification of Psoriasis: a Strategy for Precision Medicine
Recruiting · NCT05503875 · Interventional (participants receive a specific treatment) · Lead sponsor: Second Affiliated Hospital, Zhejiang University, School of Medicine
View the official record on ClinicalTrials.gov →Interventions studied
adalimumab, secukinumab, ixekizumab, guselkumab, Jak inhibitors, methotrexate
What this trial is about
Through the combination of clinical manifestations and omics, the investigators aim to explore the skin cell atlas in different stages of psoriasis lesions, establish a clinical classification standard for psoriasis, and guide the precise treatment of psoriasis.
Who can take part
Age range
18 Years to 75 Years
Sex
All (male and female)
Healthy volunteers
Yes - healthy volunteers may be accepted
Phase
Not applicable (e.g. observational or device study)
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- to 75 years of age 2.Moderate to severe chronic psoriasis, BSA≥3% 3.Duration of psoriasis≥6 months 4.Patients must be candidate for systemic therapy 5.Informed consent must be obtained 6.For female, ß-hCG test is negative and contraception is accepted
Exclusion criteria
- Having severe infections, including hepatitis, HIV and tuberculosis
- Having significant allergies to biological agents
- Having a history of malignancy
- Refusal of contraception
- Having serious or unstable/uncontrolled illnesses
Where it is running
1 location listed.
- 2nd Affiliated Hospital, School of Medicine, Zhejiang University - Hangzhou, Zhejiang, China